Bard buys Edwards's LifeStent for $74mm
CR Bard (vascular, urological, cancer, and surgical devices) has purchased cardiovascular-focused Edwards Lifesciences's LifeStent product line for $74mm in cash. It may also pay $65mm upon approval for a superficial femoral artery indication ($50mm) and for the transfer of the device manufacturing ($15mm).
- Medical Devices
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Includes Contract
- Marketing (Licensing)
- Product Purchase
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.